Research Ongoing Into Real-World Effectiveness Of PrEP For HIV Prevention

Vox: Critics worried an HIV prevention pill would encourage risky sex. So far, it hasn’t.
“…For Truvada to have a big impact, high-risk populations need to know about it and have access. Research has shown that awareness among men is still pretty low. In some of the developing countries that could most benefit from PrEP, the World Health Organization has noted, adherence to the drug — and its efficacy — were also lower [than in a study published this week in Clinical Infectious Diseases]. In other words, this is no silver bullet or magic pill for problems of health education and access…” (Belluz, 9/3).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.